Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01689246




Registration number
NCT01689246
Ethics application status
Date submitted
14/09/2012
Date registered
21/09/2012
Date last updated
14/03/2018

Titles & IDs
Public title
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Scientific title
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Secondary ID [1] 0 0
TRx-237-015
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TRx0237 150 mg/day
Treatment: Drugs - TRx0237 250 mg/day
Treatment: Drugs - Placebo

Experimental: TRx0237 250 mg/day -

Placebo comparator: Placebo -

Experimental: TRx0237 150 mg/day -


Treatment: Drugs: TRx0237 150 mg/day
TRx0237 75 mg tablets will be administered twice daily.

Treatment: Drugs: TRx0237 250 mg/day
TRx0237 125 mg tablets will be administered twice daily.

Treatment: Drugs: Placebo
Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)
Timepoint [1] 0 0
65 weeks
Primary outcome [2] 0 0
Change from Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)
Timepoint [2] 0 0
65 weeks
Primary outcome [3] 0 0
Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes
Timepoint [3] 0 0
65 weeks
Secondary outcome [1] 0 0
Change from Baseline on Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)
Timepoint [1] 0 0
65 weeks
Secondary outcome [2] 0 0
Change from Baseline on Mini-Mental Status Examination (MMSE)
Timepoint [2] 0 0
65 weeks
Secondary outcome [3] 0 0
Change in expected decline of whole brain volume as measured by brain MRI
Timepoint [3] 0 0
39 weeks and 65 weeks

Eligibility
Key inclusion criteria
* Diagnosis of all cause dementia and probable Alzheimer's disease
* Clinical Dementia Rating (CDR) total score of 1 (mild) to 2 (moderate) and MMSE score of 14-26 (inclusive)
* Age < 90 years
* Modified Hachinski ischemic score of = 4
* Females, if of child-bearing potential, must practice true abstinence or be competent to use adequate contraception and agree to maintain this throughout the study
* Subject, and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with national law is/are able to read, understand, and provide written informed consent
* Has one (or more) identified adult caregiver who is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for =2 hours/day =3 days/week; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug
* If currently taking an acetylcholinesterase inhibitor and/or memantine at the time of Screening, the subject must have been taking such medication(s) for =3 months. The dosage regimen must have remained stable for =6 weeks and it must be planned to remain stable throughout participation in the study.
* Able to comply with the study procedures
Minimum age
No limit
Maximum age
89 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Significant central nervous system (CNS) disorder other than Alzheimer's disease
* Significant focal or vascular intracranial pathology seen on brain MRI scan
* Clinical evidence or history of stroke, transient ischemic attack, significant head injury or other unexplained or recurrent loss of consciousness =15 minutes
* Epilepsy
* Major depressive disorder, schizophrenia, or other psychotic disorders, bipolar disorder, or substance (including alcohol) related disorders
* Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MRI
* Resides in hospital or moderate to high dependency continuous care facility
* History of swallowing difficulties
* Pregnant or breastfeeding
* Glucose-6-phosphate dehydrogenase deficiency
* History of significant hematological abnormality or current acute or chronic clinically significant abnormality
* Abnormal serum chemistry laboratory value at Screening deemed to be clinically relevant by the investigator
* Clinically significant cardiovascular disease or abnormal assessments
* Preexisting or current signs or symptoms of respiratory failure
* Concurrent acute or chronic clinically significant immunologic, hepatic, or endocrine disease (not adequately treated) and/or other unstable or major disease other than Alzheimer's disease
* Diagnosis of cancer within the past 2 years prior to Baseline (other than basal cell or squamous cell skin cancer or Stage 1 prostate cancer) unless treatment has resulted in complete freedom from disease for at least 2 years
* Prior intolerance or hypersensitivity to methylthioninium-containing drug, similar organic dyes, or any of the excipients
* Treatment currently or within 3 months before Baseline with any of the following medications:

* Tacrine
* Clozapine, olanzapine (and there is no intent to initiate therapy during the course of the study)
* Carbamazepine, primidone
* Drugs with a warning or precaution in the labeling about methemoglobinemia at approved doses
* Current or prior participation in a clinical trial as follows:

* Clinical trial of a product for cognition within 3 months of Screening (unless confirmed to have been randomized to placebo)
* A clinical trial of a drug, biologic, therapeutic device, or medical food in which the last dose/administration was received within 28 days prior to Baseline

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2015
Sample size
Target
Accrual to date
Final
891
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Division of Rehabilitation and Aged Care - Hornsby
Recruitment hospital [2] 0 0
Southern Neurology Pty Limited - Kogarah
Recruitment hospital [3] 0 0
Academic Department for Old Age Psychiatry, Prince of Wales Hospital - Randwick
Recruitment hospital [4] 0 0
Discipline of Psychiatry, University of Qld - Herston
Recruitment hospital [5] 0 0
Royal Adelaide Hospital Memory Trials Centre - Adelaide
Recruitment hospital [6] 0 0
Memory Unit, Neurology, The Queen Elizabeth Hospital - Woodville South
Recruitment hospital [7] 0 0
Medical and Cognitive Research Unit, Austin Health Heidelberg Repatriation Hospital - Heidelberg West
Recruitment hospital [8] 0 0
McCusker Alzheimer's Research Foundation Inc - Nedlands
Recruitment hospital [9] 0 0
Neurodegenerative Disorders Research Pty Ltd - Perth
Recruitment postcode(s) [1] 0 0
2077 - Hornsby
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
2031 - Randwick
Recruitment postcode(s) [4] 0 0
4006 - Herston
Recruitment postcode(s) [5] 0 0
5000 - Adelaide
Recruitment postcode(s) [6] 0 0
5011 - Woodville South
Recruitment postcode(s) [7] 0 0
3081 - Heidelberg West
Recruitment postcode(s) [8] 0 0
6009 - Nedlands
Recruitment postcode(s) [9] 0 0
6005 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Mississippi
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
Bulgaria
State/province [14] 0 0
Sofia
Country [15] 0 0
Canada
State/province [15] 0 0
British Columbia
Country [16] 0 0
Canada
State/province [16] 0 0
Nova Scotia
Country [17] 0 0
Canada
State/province [17] 0 0
Ontario
Country [18] 0 0
Croatia
State/province [18] 0 0
Zagreb
Country [19] 0 0
Germany
State/province [19] 0 0
Achim
Country [20] 0 0
Germany
State/province [20] 0 0
Berlin
Country [21] 0 0
Italy
State/province [21] 0 0
Milano
Country [22] 0 0
Italy
State/province [22] 0 0
Pavia
Country [23] 0 0
Italy
State/province [23] 0 0
Perugia
Country [24] 0 0
Italy
State/province [24] 0 0
Roma
Country [25] 0 0
Italy
State/province [25] 0 0
Torino
Country [26] 0 0
Italy
State/province [26] 0 0
Udine
Country [27] 0 0
Italy
State/province [27] 0 0
Varese
Country [28] 0 0
Korea, Republic of
State/province [28] 0 0
Busan
Country [29] 0 0
Korea, Republic of
State/province [29] 0 0
Incheon
Country [30] 0 0
Korea, Republic of
State/province [30] 0 0
Seongnam-si
Country [31] 0 0
Korea, Republic of
State/province [31] 0 0
Seoul
Country [32] 0 0
Malaysia
State/province [32] 0 0
Ipoh
Country [33] 0 0
Malaysia
State/province [33] 0 0
Johor Bahru
Country [34] 0 0
Malaysia
State/province [34] 0 0
Kuala Lumpur
Country [35] 0 0
Malaysia
State/province [35] 0 0
Taiping
Country [36] 0 0
Poland
State/province [36] 0 0
Bialystok
Country [37] 0 0
Poland
State/province [37] 0 0
Bydgoszcz
Country [38] 0 0
Poland
State/province [38] 0 0
Katowice
Country [39] 0 0
Poland
State/province [39] 0 0
Mosina
Country [40] 0 0
Poland
State/province [40] 0 0
Poznan
Country [41] 0 0
Poland
State/province [41] 0 0
Szczecin
Country [42] 0 0
Poland
State/province [42] 0 0
Warszawa
Country [43] 0 0
Romania
State/province [43] 0 0
Arad
Country [44] 0 0
Romania
State/province [44] 0 0
Brasov
Country [45] 0 0
Romania
State/province [45] 0 0
Bucharest
Country [46] 0 0
Romania
State/province [46] 0 0
Oradea
Country [47] 0 0
Romania
State/province [47] 0 0
Sibiu
Country [48] 0 0
Russian Federation
State/province [48] 0 0
Ekaterinburg
Country [49] 0 0
Russian Federation
State/province [49] 0 0
Moscow
Country [50] 0 0
Russian Federation
State/province [50] 0 0
Novosibirsk
Country [51] 0 0
Russian Federation
State/province [51] 0 0
Saint Petersburg
Country [52] 0 0
Singapore
State/province [52] 0 0
Singapore
Country [53] 0 0
Spain
State/province [53] 0 0
Ceuta
Country [54] 0 0
Spain
State/province [54] 0 0
Córdoba
Country [55] 0 0
Spain
State/province [55] 0 0
Madrid
Country [56] 0 0
Spain
State/province [56] 0 0
Zaragoza
Country [57] 0 0
Taiwan
State/province [57] 0 0
Changhua
Country [58] 0 0
Taiwan
State/province [58] 0 0
Kaohsiung
Country [59] 0 0
Taiwan
State/province [59] 0 0
Taichung
Country [60] 0 0
Taiwan
State/province [60] 0 0
Taipei
Country [61] 0 0
Taiwan
State/province [61] 0 0
Taoyuan
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Aberdeen
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Bath
Country [64] 0 0
United Kingdom
State/province [64] 0 0
Belfast
Country [65] 0 0
United Kingdom
State/province [65] 0 0
Birmingham
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Blackpool
Country [67] 0 0
United Kingdom
State/province [67] 0 0
Bradford
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Cannock
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Leeds
Country [70] 0 0
United Kingdom
State/province [70] 0 0
London
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Manchester
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
TauRx Therapeutics Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
Trial website
https://clinicaltrials.gov/study/NCT01689246
Trial related presentations / publications
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016 Dec 10;388(10062):2873-2884. doi: 10.1016/S0140-6736(16)31275-2. Epub 2016 Nov 16.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01689246